An interventional study of Echopulse in Breast Fibroadenoma, sponsored by Theraclion. Completed at 1 site in Bulgaria. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-19.
Sponsored by Theraclion · Not applicable, Interventional, and Treatment
This study evaluates the efficacy of the HIFU for the treatment of breast fibroadenoma with the FastScan version using assessment of patient experience and adverse event reporting.
Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.
In a previous european feasibility study performed at 4 sites (France and Bulgaria), 51 fibroadenomas in 42 patients were treated. The HIFU treatment was well tolerated and showed efficacy (mean volume reduction of 72.5% +/-16.7 at 12 months follow-up.
Diagnosis of fibroadenoma must be based on :
The requirements for the distance from the skin and the following regions of the fibroadenoma are:
Exclusion Criteria:
Echopulse HIFU
Device: Echopulse
HIFU Under ultrasound guidance
Also known as: Echopulse HIFU
Number of participants with adverse events
Time frame: 1 day post treatment
Number of participants with adverse events
Time frame: 3 days post treatment
Number of participants with adverse events
Time frame: 7 days post treatment
Change from Baseline volume of the fibroadenoma at 6 months
Time frame: 6 months post treament
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 1 day
Time frame: 1 day post treatment
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 3 days
Time frame: 3 days post treatment
Change from Baseline Patient pain intensity score (100mm visual analog scale) at 7 days
Time frame: 7 days post treatment
Patient satisfaction questionnaire
Time frame: 6 months post treatment
Number of participants with absence of palpable lesion
Time frame: 3 months post treatment
Number of participants with absence of palpable lesion
Time frame: 6 months post treatment
Patient Cosmetic evaluation as measured by questionnaire
Time frame: 6 months post treatment
Investigator rated evaluation of the device
Time frame: Post treatment Day 0
Change from Baseline gland vascularization at 3 months
Time frame: 3 months post treatment
Change from Baseline gland vascularization at 6 months
Time frame: 6 months post treatment
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theraclion